Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

Journal of Clinical Pharmacology

Volumn 54, Issue 7, 2014, Pages 818-827

  Struemper, Herbert ^a   Sale, Mark ^b   Patel, Bela R ^a   Østergaard, Mikkel ^c   Österborg, Anders ^d   Wierda, William G ^e   Hagenbeek, Anton ^f   Coiffier, Bertrand ^g   Jewell, Roxanne C ^a  

^a GLAXOSMITHKLINE   (United States)

^b Next Level Solutions LLCNC   (United States)

^c Mental Health Center Glostrup   (Denmark)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

chronic lymphocytic leukemia; follicular lymphoma; ofatumumab; Pharmacokinetics; rheumatoid arthritis

Indexed keywords

BOVINE SERUM ALBUMIN; CD19 ANTIGEN; CD20 ANTIGEN; IMMUNOGLOBULIN G; OFATUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; RHEUMATOID ARTHRITIS; ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MODEL; BLOOD; CHEMISTRY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; DRUG MONITORING; DRUG RESISTANCE; FEMALE; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MALE; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROCEDURES; RECURRENT DISEASE; REPRODUCIBILITY; VALIDATION STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RECURRENCE; REPRODUCIBILITY OF RESULTS;

EID: 84902003421     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.268     Document Type: Article

References (21)

1. Teeling JL, Mackus WJM, Wiegman LJJM, van den Brakel JHN, Beers SA, French RR, van Meerten T, Ebeling S, Vink T, Slootstra JW, Parren PWHI, Glennie MJ, van de Winkel JGJ,. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 2006; 177: 362-371. (Pubitemid 43939148)
2. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC,. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am. J. Hematol. 1992; 40: 259-263.
3. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PWHI, Hack CE, Dechant M, Valerius T, van de Winkel JGJ, Glennie MJ,. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004; 104: 1793-1800. (Pubitemid 39202289)
4. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T,. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood. 2008; 111: 1094-1100. (Pubitemid 351213387)
5. Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, Frederiksen H, van Oers MHJ, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Robak T, Petersen J,. Pharmacokinetics and pharmacokinetic/ pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1-2 study. Br. J. Haematol. 2010; 150: 58-71.
6. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJS, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Österborg A,. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 2010; 28: 1749-1755.
7. Wierda WG, Kipps TJ, Mayer J, Robak T, Dyer MJS, Furman RR, Hillmen P, Stilgenbauer S, Williams CD, Trneny M, Cartron G, Hernandez-Ilizaliturri FJ, Padmanabhan S, Chan GW, Gupta IV, Gorczyca MM, Davis RL, Losic N, Lisby S, Österborg A,. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts). 2010; 116: 921.
8. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Waldwski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J,. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111: 5486-5495.
9. Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S,. Ofatumumab,a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs. Arthritis Rheum. 2010; 62: 2227-2238.
10. Sale M, Jewell RC, Patel BR,. Ofatumumab population pharmacokinetic analysis in patients with chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and rheumatoid arthritis (RA). American Conference on Pharmacometrics (ACoP). San Diego, CA: April, 2011.
11. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO,. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011; 13: 143-151.
12. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 2010; 49: 633-659.
13. Defoiche J, Debacq C, Asquith B, Zhang Y, Burny A, Bron D, Lagneaux L, Macallan D, Willems L,. Reduction of B cell turnover in chronic lymphocytic leukaemia. Br. J. Haematol. 2008; 143: 240-247.
14. Waldmann TA, Strober W,. Metabolism of immunoglobulins. Prog. Allerg. 1969; 13: 1-110.
15. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A, Lewis SM, Najean Y,. Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br. J. Haematol. 1995; 89: 748-756.
16. Roopenian DC, Sun VZ,. Clinical ramifications of the MHC family Fc receptor FcRn. J. Clin. Immunol. 2010; 30: 790-797.
17. Morell A, Terry WD, Waldmann TA,. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 1970; 49: 673-680.
18. Struemper H, Chen C, Cai W,. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J. Clin. Pharmacol. 2013; 53: 711-720.
19. Ma P,. Theoretical considerations of target-mediated drug disposition models: Simplifications and approximations. Pharm. Res. 2012; 29: 866-882.
20. Rossmann ED, Lundin J, Lenkei R, Mellstedt H, Österborg A,. Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies. Hematol. J. 2001; 2: 300-306. (Pubitemid 32976373)
21. Ng CM, Bruno R, Combs D, Davies B,. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J. Clin. Pharmacol. 2005; 45: 792-801. (Pubitemid 40875331)